Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma
  

<< back

By: Matthias Augustin et al.
Courtesy Weleda USA

Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma. By Matthias Augustin et al.

Category: Cancer and Iscador

Published by Arzneim.-Forsch./Drug Research on 1/1/2005

Summary: A long-term Iscador treatment in patients with mean- to high-risk primary malignant melanoma appears to be safe. A tumor enhancement was not observed. In comparison with an untreated parallel control group from the same cohort the results of the mistletoe treatment show a significant survival advantage in the UICC-/AJCC stages II-III.


Read full article (.PDF format)





<< back

Dynamic Content Management by ContentTrakker